DENV-3 precursor membrane (prM) glycoprotein enhances E protein immunogenicity and confers protection against DENV-2 infections in a murine model

References

• Li J, Gao N, Fan D, Chen H, Sheng Z, Fu S, Liang G, An J. Cross-protection induced by Japanese encephalitis vaccines against different genotypes of Dengue viruses in mice. Sci Rep. 2016;6(1):19953. doi:10.1038/srep19953.
   PubMedGoogle Scholar
• Castillo JA, Castrillón JC, Diosa-Toro M, Betancur JG, St Laurent G, Smit JM, Urcuqui-Inchima S. Complex interaction between dengue virus replication and expression of miRNA-133a. BMC Infect Dis. 2016;16(1):29. doi:10.1186/s12879-016-1364-y.
   PubMedGoogle Scholar
• Lindenbach B, Thiel H, Rice C. Flaviviridae: The viruses and their replication. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE, editors. Fields virology. Philadelphia (PA): Lippincott Williams & Wilkins; 2007. p. 1101–52.
   Google Scholar
• Suzuki Y, Chin W-X, Han Q, Ichiyama K, Lee CH, Eyo ZW, Ebina H, Takahashi H, Takahashi C, Tan BH, et al. Characterization of RyDEN (C19orf66) as an interferon-stimulated cellular inhibitor against Dengue Virus replication. PLoS Pathog. 2016;12(1):e1005357. doi:10.1371/journal.ppat.1005357.
   PubMed Web of Science ®Google Scholar
• Kulkarni MR, Numoto N, Ito N, Kuroda Y. Modeling and experimental assessment of a buried Leu-Ile mutation in dengue envelope domain III. Biochem Biophys Res Commun. 2016;471(1):163–68. doi:10.1016/j.bbrc.2016.01.159.
   PubMed Web of Science ®Google Scholar
• Idris F, Muharram SH, Diah S. Glycosylation of dengue virus glycoproteins and their interactions with carbohydrate receptors: Possible targets for antiviral therapy. Arch Virol. 2016;161(7):1751–60. doi:10.1007/s00705-016-2855-2.
   PubMed Web of Science ®Google Scholar
• Roby JA, Hall RA, Setoh YX, Khromykh AA. Post-translational regulation and modifications of flavivirus structural proteins. J Gen Virol. 2015;96(7):1551–69. doi:10.1099/vir.0.000097.
   PubMedGoogle Scholar
• Gack MU, Diamond MS. Innate immune escape by Dengue and West Nile viruses. Curr Opin Virol. 2016;20:119–28. doi:10.1016/j.coviro.2016.09.013.
   PubMed Web of Science ®Google Scholar
• Galula JU, Shen W-F, Chuang S-T, Chang GJJ, Chao D-Y. Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine. J Virol. 2014;88(18):10813–30. doi:10.1128/JVI.00810-14.
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim YN, Truong TT, Thu Thuy NT, Mai LQ, Jang Y-S. Development of a monoclonal antibody specific to envelope domain III with broad-spectrum detection of all four dengue virus serotypes. Biochem Biophys Res Commun. 2016;473(4):894–98. doi:10.1016/j.bbrc.2016.03.146.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick BD, Whitehead SS, Pierce KK, Tibery CM, Grier PL, Hynes NA, Larsson CJ, Sabundayo BP, Talaat KR, Janiak A, et al. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. Sci Transl Med. 2016;8(330):330ra36. doi:10.1126/scitranslmed.aaf1517.
   PubMed Web of Science ®Google Scholar
• Orellano PW, Reynoso JI, Stahl H-C, Salomon OD. Cost-utility analysis of dengue vaccination in a country with heterogeneous risk of dengue transmission. Vaccine. 2016;34(5):616–21. doi:10.1016/j.vaccine.2015.12.040.
   PubMed Web of Science ®Google Scholar
• Porter KR, Raviprakash K. Nucleic acid (DNA) immunization as a platform for dengue vaccine development. Vaccine. 2015;33(50):7135–40. doi:10.1016/j.vaccine.2015.09.102.
   PubMed Web of Science ®Google Scholar
• Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, Savarino S, Zambrano B, Moureau A, Khromava A, et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med. 2018;379(4):327–40. doi:10.1056/NEJMoa1800820.
   PubMed Web of Science ®Google Scholar
• Rosenbaum L. Trolleyology and the dengue vaccine dilemma. N Engl J Med. 2018;379(4):305–07. doi:10.1056/NEJMp1804094.
   PubMed Web of Science ®Google Scholar
• Galula JU, Salem GM, Chang GJJ, Chao D-Y. Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era? Hum Vaccin Immunother. 2019;15(10):2328–36. doi:10.1080/21645515.2019.1643676.
   PubMed Web of Science ®Google Scholar
• Chiang C-Y, Liu S-J, Hsieh C-H, Chen M-Y, Tsai J-P, Liu -H-H, Chen I-H, Chong P, Leng C-H, Chen H-W, et al. Recombinant lipidated dengue-3 envelope protein domain III stimulates broad immune responses in mice. Vaccine. 2016;34(8):1054–61. doi:10.1016/j.vaccine.2016.01.009.
   PubMed Web of Science ®Google Scholar
• Putri DH, Sudiro TM, Yunita R, Jaya UA, Dewi BE, Sjatha F, Konishi E, Hotta H, Sudarmono P. Immunogenicity of a candidate DNA vaccine based on the prM/E genes of a dengue type 2 virus cosmopolitan genotype strain. Jpn J Infect Dis. 2015;68(5):357–63. doi:10.7883/yoken.JJID.2014.313.
   PubMed Web of Science ®Google Scholar
• Abrao EP, Espósito DLA, Lauretti F, Fonseca BALD. Dengue vaccines: What we know, what has been done, but what does the future hold? Rev Saude Publica. 2015;49:60. doi:10.1590/S0034-8910.2015049006146.
   PubMed Web of Science ®Google Scholar
• Oliveira MDD, et al. Enhancement of dengue-2 E protein expression by the expression of the precursor membrane protein (Prm) of the dengue-3 virus. J Vaccines Vaccine. 2013;4:182. doi:10.4172/2157-7560.1000182.
   Google Scholar
• Jimenez RO, da Fonseca BAL. Recombinant plasmid expressing a truncated dengue-2 virus E protein without co-expression of prM protein induces partial protection in mice. Vaccine. 2000;19(6):648–54. doi:10.1016/S0264-410X(00)00247-4.
   PubMed Web of Science ®Google Scholar
• Russell PK, et al. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol. 1967;99(2):285–90.
   PubMed Web of Science ®Google Scholar
• Azevedo AS, Gonçalves AJS, Archer M, Freire MS, Galler R, Alves AMB. The synergistic effect of combined immunization with a DNA vaccine and chimeric yellow fever/dengue virus leads to strong protection against dengue. PLoS One. 2013;8(3):e58357. doi:10.1371/journal.pone.0058357.
   PubMed Web of Science ®Google Scholar
• Falgout B, Bray M, Schlesinger JJ, Lai CJ. Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. J Virol. 1990;64(9):4356–63. doi:10.1128/JVI.64.9.4356-4363.1990.
   PubMed Web of Science ®Google Scholar
• De Paula SO, et al. A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge. Arch Virol. 2008;153(12):2215–23. doi:10.1007/s00705-008-0250-3.
   PubMed Web of Science ®Google Scholar
• Prompetchara E, et al. Induction of neutralizing antibody response against four dengue viruses in mice by intramuscular electroporation of tetravalent DNA vaccines. PLoS One. 2014;9(6):e92643. doi:10.1371/journal.pone.0092643.
   PubMed Web of Science ®Google Scholar
• Wichmann O, Vannice K, Asturias EJ, de Albuquerque Luna EJ, Longini I, Lopez AL, Smith PG, Tissera H, Yoon I-K, Hombach J, et al. Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness. Vaccine. 2017;35(42):5535–42. doi:10.1016/j.vaccine.2017.08.066.
   PubMed Web of Science ®Google Scholar
• Amorim JFS, et al. Dengue infection in mice inoculated by the intracerebral route: Neuropathological effects and identification of target cells for virus replication. Sci Rep. 2019;9(1):17926. doi:10.1038/s41598-019-54474-7.
   PubMedGoogle Scholar
• Heinz FX, Allison SL, Stiasny K, Schalich J, Holzmann H, Mandl CW, Kunz C. Recombinant and virion-derived soluble and particulate immunogens for vaccination against tick-borne encephalitis. Vaccine. 1995;13(17):1636–42. doi:10.1016/0264-410X(95)00133-L.
   PubMed Web of Science ®Google Scholar
• Konishi E, Fujii A, Mason PW. Generation and characterization of a mammalian cell line continuously expressing Japanese encephalitis virus subviral particles. J Virol. 2001;75(5):2204–12. doi:10.1128/JVI.75.5.2204-2212.2001.
   PubMed Web of Science ®Google Scholar
• Konishi E, Terazawa A, Fujii A. Evidence for antigen production in muscles by dengue and Japanese encephalitis DNA vaccines and a relation to their immunogenicity in mice. Vaccine. 2003;21(25–26):3713–20. doi:10.1016/S0264-410X(03)00376-1.
   PubMed Web of Science ®Google Scholar
• Konishi E, et al. Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes. J Virol. 1998;72(6):4925–30.
   PubMed Web of Science ®Google Scholar
• Konishi E, et al. A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice. Vaccine. 2000;18(11–12):1133–39. doi:10.1016/S0264-410X(99)00376-X.
   PubMed Web of Science ®Google Scholar
• Blair PJ, KOCHEL T, RAVIPRAKASH K, GUEVARA C, SALAZAR M, WU S, OLSON J, PORTER K. Evaluation of immunity and protective efficacy of a dengue-3 pre-membrane and envelope DNA vaccine in Aotus nancymae monkeys. Vaccine. 2006;24(9):1427–32. doi:10.1016/j.vaccine.2005.09.032.
   PubMed Web of Science ®Google Scholar
• Lindenbach BD, Rice CM. Molecular biology of flaviviruses. Adv Virus Res. 2003;59:23–61.
   PubMed Web of Science ®Google Scholar
• Lu H, Xu X-F, Gao N, Fan D-Y, Wang J, An J. Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM/E and NS1: Their immunity and protective efficacy in mice. Mol Immunol. 2013;54(2):109–14. doi:10.1016/j.molimm.2012.11.007.
   PubMed Web of Science ®Google Scholar
• Kamal RP, et al. Inactivated H7 influenza virus vaccines protect mice despite inducing only low levels of neutralizing antibodies. J Virol. 2017;91(20). doi:10.1128/JVI.01202-17.
   PubMed Web of Science ®Google Scholar
• Leclerc C, Dériaud E, Rojas M, Whalen RG. The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. Cell Immunol. 1997;179(2):97–106. doi:10.1006/cimm.1997.1161.
   PubMed Web of Science ®Google Scholar
• Tighe H, Corr M, Roman M, Raz E. Gene vaccination: Plasmid DNA is more than just a blueprint. Immunol Today. 1998;19(2):89–97. doi:10.1016/S0167-5699(97)01201-2.
   PubMedGoogle Scholar
• Lima DM, Paula SOD, França RFDO, Palma PVB, Morais FR, Gomes-Ruiz AC, Aquino MTPD, Fonseca BALD. A DNA vaccine candidate encoding the structural prM/E proteins elicits a strong immune response and protects mice against dengue-4 virus infection. Vaccine. 2011;29(4):831–38. doi:10.1016/j.vaccine.2010.10.078.
   PubMed Web of Science ®Google Scholar
• Raviprakash K, et al. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. Vaccine. 2000;18(22):2426–34. doi:10.1016/S0264-410X(99)00570-8.
   PubMed Web of Science ®Google Scholar
• Xiao S, Shiloach J, Betenbaugh MJ. Engineering cells to improve protein expression. Curr Opin Struct Biol. 2014;26:32–38. doi:10.1016/j.sbi.2014.03.005.
   PubMed Web of Science ®Google Scholar